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Among radiopharmaceuticals of positron emission tomography (PET), 
18
F-
Fluorodeoxyglucose (
18
F-FDG) made from commercialized automated synthesis module 
is the most frequently used in tumor diagnoses.  But the false positive findings, such as 
infectious tissues and post-operative surgical conditions, show strong uptake of 
18
F-FDG 
in PET scans which requires extra clinical procedures to confirm the results. Moreover, 
the false negative findings, such as low glycolytic activity tumors, reduce the accuracy of 
PET scans. Therefore, there will be new PET radiopharmaceuticals to redeem the defects 
of 
18
FDG-PET applications.    
Current commercialized automated synthesis modules are suitable for clinical 
use, but researchers are difficult to modify these modules to synthesize their own 
radiopharmaceuticals. In this study, we developed a multi-purpose automated synthesis 
module for production of novel PET radiopharmaceuticals, such as gallium-68-
ethylenedicysteine-glucosamine (
68
Ga-ECG), [
18
F]fluoropropyl-α-methyltyrosine (
18
F-
vi 
 
FPAMT), and [
18
F]fluoro-5-propylhydroxy tryptophan (
18
F-FTP). The specifications of this 
module are the flexibility for editing synthesis recipes, the stable integration of its 
hardware and software, the rapid heating process, and the friendly user interface. The 
synthesis steps of nonradioactive standards for these three radiopharmaceuticals were 
developed, and the chemical structures and purities of nonradioactive references were 
confirmed. Then, the manual synthesis recipes of radiopharmaceuticals were followed 
the synthesis recipes of nonradioactive standards, and the yields and radiochemical 
purities of these radiopharmaceuticals were demonstrated in an acceptable range. Last, 
the manual synthesis recipes of these drugs were transformed to the automated 
synthesis recipes which can be practiced in this multi-purpose automated synthesis 
module. 
The results showed this automated module is capable of synthesizing different 
radiopharmaceuticals. The pH value and radiochemical purity of automated synthesis 
are as good as the manual synthesis. Although the yields of automated syntheses are 
lower than the manual syntheses, the flexible functions of this module provide the 
opportunity for optimization of automated synthesis methods.     
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1 Chapter 1 Introduction 
1.1 Introduction of molecular imaging  
Molecular imaging is an emerging field which targets to visualize biological and 
biochemical events in the molecular level of living subjects without invasive methods(1). 
Molecular imaging, such as positron emission tomography (PET), and single-photon 
emission computed tomography (SPECT), uses different types of energy and the 
acquisition equipment for various applications(2-4). Other medical imaging techniques 
without specific molecular targets, such as magnetic resonance imaging (MRI), 
ultrasound imaging (US), and computed tomography (CT), can provide better spatial 
resolution for structural imaging and detect anatomical changes for specific diseases(5-
7).  The comparisons of medical imaging modalities are listed in Table 1.1.  A SPECT scan 
uses a gamma camera that rotates around the patient to detect the distribution of a 
radiotracer in the body. SPECT has acceptable penetration depth, but its deficiency is 
limited in spatial resolution which restricts its usages in molecular imaging(8).  A PET 
scan is a three-dimensional image coming from reconstructing the data of numerous 
detections of pair photons which are produced from annihilation of radiotracers in the 
living subject(9). PET is suitable for oncology imaging because of its high sensitivity, 
sufficient depth penetration and better spatial resolution than SPET. PET and SPECT 
combined with CT can provide detail information on the anatomy and the function of 
organs and tissues (10, 11). Other experimental molecular imaging technologies, such as 
fluorescence imaging, and bioluminescence imaging, can provide high sensitive images 
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by selection of proper imaging probes, but it is limited in the penetration of tissue 
depth(1).  
 
Table 1.1 Comparisons of Imaging Technologies 
Imaging   
Technology 
Limitation of Spatial 
Resolution (mm) 
Detection Limitation of Tracer/Contrast 
Material Concentration (mol/kg) 
MRI 1.0 10
-5
 
CT 0.3 10
-3
 
US 0.3 (5 MHz) Difficult quantitative by contrast material 
SPECT 7 10
-8
~10
-10
 
PET 3 10
-9
~10
-12
 
 
1.2 Principle of PET radiopharmaceuticals 
A radiopharmaceutical is a radiochemical whose chemical substance has 
radioactive atoms, and it is administrated safely to humans and animals for diagnosis or 
therapeutic effect by U.S. Food and Drug Administration (FDA) regulations. In oncology, 
diagnosis radiopharmaceuticals can interact with various biomarkers which can be 
linked to different biological processes of tumor progression, including cell proliferation, 
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metabolism, cell migration, receptor expression, hypoxia, and angiogenesis(12-17). The 
labeling methods of radiopharmaceuticals can be described as the radioisotopic 
labeling(18) and the structure modifications of its original molecular. The definition of 
radioisotopic labeling is the replacements of a stable atom in a chemical compound with 
its radioisotope without modification its original structure. The radioisotopic-labeling 
chemical is suitable for applications because it shares identical chemical and biological 
properties of its original molecular. Hydrogen, carbon, nitrogen, oxygen, phosphorus, 
sulfur, and fluorine are the basic atoms in structures of pharmaceuticals, but 
radioisotopic-labeling of these atoms is limited to decay-mode, half-life, and synthesis 
methods(18). Only carbon-11 choline, carbon-14 urea, and fluorine-18 sodium fluoride 
are FDA-approved radioisotopic labeling radiopharmaceuticals(19). The other synthesis 
method of radiopharmaceuticals is to label a radioisotope to the target chemicals within 
modifications of its original structure, and often slightly changes the chemical or 
biological properties of the original molecular(18). These perturbations may be 
deleterious or advantageous for applications(20). However, the structure modification 
method provides more options for synthesis of radiopharmaceuticals. Besides FDA-
approved radioisotopic radiophamaceuticals, other FDA-approved radiopharmaceuticals, 
such as fluorine-18 fluorodeoxyglucose (
18
F-FDG) and technetium-99m pentetate, are 
radio-nonisotopic labeling radiopharmaceuticals. FDA-approved PET 
radiopharmaceuticals and clinical indications are shown in Table 1.2. 
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Table 1.2 FDA-Approved PET Radiopharmaceuticals 
Name Approved Clinical Indications 
Carbon-11 Choline Carbon-11 choline injection is indicated for PET 
imaging of patients with suspected prostate cancer 
recurrence and non-informative bone scintigraphy, 
CT or MRI. Suspected prostate recurrence is based 
upon elevated blood prostate specific antigen (PSA) 
levels following initial therapy. 
Fluorine-18 Florbetapir (Amyvid) Fluorine-18 florbetapir is indicated for PET imaging 
of the brain to estimate β-amyloid neuritic plaque 
density in adult patients with cognitive impairment 
who are being evaluated for Alzheimer's Disease 
(AD) and other causes of cognitive decline. 
Fluorine-18 Sodium Fluoride Fluorine-18 sodium fluoride is PET bone imaging 
agent to delineate areas of altered osteogenesis 
Fluorine-18 Fludeoxyglucose Fluorine-18 fludeoxyglucose is indicated in PET 
imaging for assessment of abnormal glucose 
metabolism to assist in the evaluation of malignancy 
in patients with known or suspected abnormalities 
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found by other testing modalities, or in patients with 
an existing diagnosis of cancer. 
Nitrogen-13 Ammonia Nitrogen-13 ammonia is indicated for diagnostic PET 
imaging of the myocardium under rest or 
pharmacologic stress conditions to evaluate 
myocardial perfusion in patients with suspected or 
existing coronary artery disease. 
Rubidium-82 Chloride Rubidium-82 chloride is PET myocardial perfusion 
agent that is useful in distinguishing normal from 
abnormal myocardium in patients with suspected 
myocardial infarction. 
 
 
1.2.1 The selection of PET radioisotopes    
A nuclide is a combination of protons, neutrons, and its nuclear energy in a 
nucleus of an atom. Unstable nuclides, called radionuclides, transform to nuclides by 
emitting radiations, such as α particles, β- particles, β+ particles, electron capture, and 
isomeric transition. Radionuclide with an excess proton may have positron decay where 
the proton is converted into a neutron, a positron (β+ particles), and a neutrino. When a 
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positron interact an electron of an atom in a matter, both particles will annihilated to 
produce two 511 keV photons with opposite directions (180°) at the same time. 
Detection of the two photons in coincidence by detectors is the basis of PET(9).  
Commonly used PET imaging radionuclides and their characters are listed in 
Table 1.3. These radioisotopes can be produced from either a cyclotron, like 
11
C, 
13
N, 
15
O, 
18
F, and 
64
Cu or in a generator, like 
68
Ge/
68
Ga and 
82
Sr/
82
Rb. Because carbon, nitrogen, 
and oxygen are the major atoms of organic compounds, 
11
C, 
13
N, and 
15
O are ideal 
radionuclides for radioisotopic labeling. However, the positron path of these 
radionuclides is longer than the path of 
18
F (Max: 0.02 cm in water) which is similar to 
the resolution of current PET camera. In addition, these PET isotopes with particulate 
short half-life, such as 
11
C, 
13
N, and 
15
O, lose major radioactivity when these isotopes are 
transferred to remote PET imaging centers without a built-in cyclotron. Generally, 
radiopharmaceuticals with these radioisotopes are difficult practiced in remote PET 
imaging centers or research facilities if the transport time is over twice of half-life of 
these radioisotopes.  
Table 1.3 Suitable Radionuclides for PET Imaging 
Radionuclide Source β+(MeV) Half-life 
11
C 
cyclotron 0.959 20 minutes 
13
N 
cyclotron 1.197 9.97 minutes 
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15
O 
cyclotron 1.738 2.03 minutes 
18
F 
cyclotron 0.635 110 minutes 
124
I 
cyclotron 2.13 4.2 days 
68
Ga 
generator 1.9 68 minutes 
64
Cu 
cyclotron 2.91 12.8 hours 
82
Rb generator 3.15 76 seconds 
 
Besides PET radioisotopes produced by a cyclotron, generator-produced 
radioisotopes, such as 
68
Ge/
68
Ga and 
82
Sr/
82
Rb, are alternative sources of PET 
radionuclide for a remote imaging facility because a generator is much cheaper and 
more compact than a cyclotron. The extra short half-life of 
82
Rb is not suitable for 
evaluation of biological events in the living organs. Therefore, 
18
F and 
68
Ga were 
selected as target radionuclides for automated radiopharmaceuticals synthesis in this 
project.  
 
1.3 Radiochemistry of PET radiopharmaceuticals: Fluorine 18 and Gallium 68 
Radiochemistry is defined as “the chemical study of radioactive elements, both 
natural and artificial, and their use in the study of chemical processes”(21). Other than 
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chemistry, there is a very unique aspect in radiochemistry, infinitesimal reaction 
quantities of radioactive elements with high outcomes in applications. For example, the 
average dosage of 
18
F-FDG for a patient is 10mCi, and this dose contains only 10
-10
g of 
fluorine-18. The reaction rate of chemical process is affected by concentrations of 
reagents, reaction orders, pressure, temperature, solvent, catalyst, and reaction surface 
area(22). Among these factors, concentrations of reagents and reaction orders have the 
major impact on the reaction rate of the radiochemical process because of the 
infinitesimal reaction quantities of radioactive elements.  
 
For radiochemical procedures, ultra-small quantities of radioisotopes are difficult 
to manipulate because they are easily lost by adherence to the container wall, and 
filters. Chemists sometimes use the chemically identical material, the stable form of the 
radioisotope, which is added into the reaction for decreasing the loss of radioisotope by 
occupying these spaces. Or chemists use the carrier which can carry radioisotope in the 
chemical reactions. The definition of carrier in Gold Book of the International Union of 
Pure and Applied Chemistry (IUPAC) is “A substance in appreciable amount which, when 
associated with a trace of a specified substance, will carry the trace with it through a 
chemical or physical process”. In addition, carrier-added radiochemical process can 
decrease the loss of the radioactivity during synthesis by increasing the reaction rate. 
Except for the zero order reaction, reaction rates in higher order reactions can rise by 
increasing concentrations of reagents.  However, specific activity (SA) of radiotracers is 
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lower by these non-radioactive carries which can easily saturate low density target 
receptors and decrease the sensitivity of applications. The definition of SA in the Gold 
Book of IUPAC is “For a specified isotope, or mixture of isotopes, the activity of a 
material divided by the mass of the material”. To avoid the decreasing of SA, no-carrier 
added methods are developed for radiochemical synthesis.  
 
1.3.1 Radiochemistry of Fluorine-18  
By using particular nuclear reactions, target materials, and beam energy, current 
cyclotrons can produce two different forms of fluorine-18, [
18
F]F2(23) and [
18
F]F
-
(24). 
[
18
F]F2 is the gas phase which is used for electrophilic substitution(25); [
18
F]F
- 
 is in the 
liquid phase which is used for nucleophilic substitution(26).  
 
1.3.1.1 Electrophilic Fluorination 
Because [
18
F]F2 is extremely corrosive and reactive gas which causes non-
selective reactions, it is difficult to be manipulated correctly in chemical procedures. 
After adding carriers, such as xenon and ammonium acetate, [
18
F]F2 is transferred into 
less reactive and more selective fluorinated agents, like xenon difluoride(27), and 
acetyhypofluorite(28) (Figure 1.1).  
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Figure 1.1 Preparations of electrophilic fluorination reagents 
These fluorinated-carriers are used to transfer fluorine ions to electron-rich 
substrates, such as carbanions and aromatic compounds (Figure 1.2) (29), which can’t 
be directly fluorinated by nucleophilic methods. Due to carrier-added reactions, 
electrophilic fluorination has low specific activity which limited its usage in some 
applications. In addition, side products are produced during carrier fluorination.  To 
overcome this problem, some reactive groups of the target chemicals are protected 
from fluorination to improve labeling-efficiency of fluorinated carriers(30).  
 
Figure 1.2 Electrophilic syntheses of 6-[
18
F] FDOPA 
1.3.1.2 Nucleophilic Fluorination 
Not only production of corrosive F2 for electrophilic fluorination, a cyclotron can 
produce radioactive fluoride ions from irradiation of O-18-enriched water for 
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nucleophilic fluorination which is a no-carrier added synthesis method(31). [
18
F]F
-
 is 
quite unreactive in aqueous form, and it needs certain procedures to increase its 
nucleophilicity. After irradiation of O-18-enriched water, radioactive fluoride anions are 
easily to form alkaline metal fluoride (potassium fluoride, cesium fluoride, or silver 
fluoride), and hydrogen fluoride. In order to remove impurities, the aqueous fluoride 
solution is loaded through anion exchange resins which can trap fluoride. After that, 
phase transfer catalysts in aprotic dipolar solvent, such as potassium/Krytofix 222 in 
acetonitrile or tetraalkylammonium salts in dimethylformamide, are loaded through the 
resins to capture [
18
F]fluoride ions. During this procedure, the bases, potassium oxalate 
or potassium carbonate, are added with phase transfer catalysts in aprotic dipolar 
solvent to prevent the occurrence of hydrogen fluoride(32).  Then, azeotropic distillation 
with acetonitrile is used several times to remove residual water for obtaining “free” or 
“naked” form of fluoride ion. Nucleophilic fluorination is frequently carried out because 
of its easy preparation and high specific activity (33-35). Methods of nucleophilic 
fluorination range from aromatic and aliphatic substitution.  
 
 
1.3.1.2.1 Aliphatic nucleophilic substitution 
Nucleophilic fluorination of aliphatic compounds is the SN2 reaction whose 
reaction rate is affected by two factors, leaving groups and solvents(36). The typical 
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leaving groups are halogens, triflate, nosylate, tosylate, and mesylate. The typical 
solvents are polar aprotic solvents, such as acetonitrile, dimethyl sulfoxide, NN-
dimethylformamide, NN-dimethylacetamide, tetrahydrofuran, and acetone(37). While 
aliphatic nucleophilic substitution can often be a one-step reaction, it is often followed 
by a deprotection step (38)(Figure 1.3). Except for the reaction rate, elimination of side 
product, such as fluorinated leaving groups, can also improve fluorination efficiency(38).   
 
 
 
Figure 1.3 Synthesis of [
18
F]-FDG by aliphatic nucleophilic fluorination 
 
 
 
13 
 
1.3.1.2.2 Aromatic nucleophilic substitution  
This reaction requires the leaving group in the aryl ring with one electron-
withdrawing group at an ortho position or a para position. The common leaving groups, 
listed in the order of its leaving ability, are I < Br < Cl < F < NO2 < N
+
Me3(39). The 
electron-withdrawing groups, listed in the order of its activating effect, are 3-NO2 < 4-
CH3CO < 4-CN < 4-NO2(40). The most common solvents in this reaction are dimethyl 
sulfoxide, and N, N-dimethylacetamide (Figure 1.4)(41).  
 
Figure 1.4 Synthesis of [
18
F]FMTEB by aromatic nucleophilic substitution 
 
For aromatic compounds without electron-withdrawing groups, Balz-Schiemann 
reaction or Wallach reaction(42) is an option for nucleophilic fluorination. However, 
these reactions require carriers for the preparation of fluoroboric acid. This reaction is 
rarely used because its low SA and radiochemical yield. For nucleophilic heteroaromatic 
fluorination, especially pyridines, even if there are no electron-withdrawing groups in 
the aromatic ring, the quantitative radiochemical yield is achieved (Figure 1.5)(35).  
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Figure 1.5 Synthesis of [
18
F] pyridine by nucleophilic heteroaromatic fluorination 
 
1.3.2 Radiochemistry of 
68
Ga 
Radionuclide generators have significant research and clinical interest because 
they allow radioactive studies without an on-site cyclotron. Gallium-68 generators have 
the following advantages over other positron-emitting radionuclides generators(43). 
Gallium-68 is high efficiency positron emitter (89%) which is a suitable radionuclide for 
PET radiopharmaceuticals. In addition, 
68
Ga has a physical half-life of 68 minutes which 
provides enough time-window for observing biological events. The parent isotope of 
68
Ga generator, 
68
Ge, has long half-life of 271 days, and this feature allows 
68
Ga 
generator has long life-cycle and is available for long distance shipment. 
68
Ga generators 
have organic or inorganic matrices to separate 
68
Ge and 
68
Ga by immobilization 
68
Ge in 
the oxidation state IV+. After elution with hydrochloric acid from generators, the +3 
oxidation state of 
68
Ga is the most stable form in the acid solution. Ga
3+
 ion is a hard 
Lewis acid with coordination number of four to six. Chelators act as Lewis bases which 
provide at least two pairs of electrons to bond Ga
3+
. The majority of chelators for Ga
3+
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are tetradentate, pentadentate, and hexadentate ligands (44). If the chelator, besides 
binding the metal cation, also provides other functional groups which conjugate a 
targeting molecular for biological events, it is called a bifunctional chelator(45). DOTA-
tris(tBu) is the monoactive bifuntional prochelator, and can be coupled to the 
somatostatin analogue Tyr
3
-Lys
5
(BOC)-octreotide. After deprotection in trifluoroacrtic 
acid with water, DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) was ready to react with 
68
Ga 
ions for constituting the coordination complexes, 
68
Ga-DOTA-D-Phe1-Tyr3-octreotide 
(
68
Ga-DOTATOC)(46). 
68
Ga-DOTATOC demonstrates thermodynamically and kinetically 
stable in clinical studies, and is an octreotide analogue which can interact with 
somatostatin receptors for diagnosis of certain types of cancers (47-52).  
 
1.4 Automated synthesis devices 
Merrifield and Stewart proposed the first apparatus for automated synthesis of 
solid phase peptides in 1966(53). Following this successful and pioneer prototype, other 
automated systems share the same concepts for different applications, including 
radiosynthesis. For radiochemistry, Wolf et al first synthesized 
18
F-FDG by electrophilic 
fluorination in 1976(54), and Barrio et al developed a remote, semiautomated system to 
synthesize 
18
F-FDG by electrophilic fluorination in 1981(55). Before popularity and 
improvement of microprocessor, semiautomated and automated synthesis systems 
could provide limited functions for radiosynthesis, and the availability of 
18
F-FDG 
produced by electrophilic fluorination is limited by its low yield. Until 1986, Hamacher et 
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al synthesized 
18
F-FDG by using kryptofix 222 as a phase transfer catalyst, and this 
nucleophilic fluorination provided short synthesis time and high radiochemical yield(56, 
57). This method improved the availability of 
18
F-FDG, and more 
18
F-FDG researches 
were carried out, especially in oncology (58-62). After FDA approvals of clinical usages 
for 
18
F-FDG in tumor glucose metabolism in 2000, there are strong demands for the 
usage of 
18
F-FDG automated synthesizers in clinics.  
Current common commercially available automated synthesis modules for 
production of 
18
F-FDG are Explora FDG4 (Siemens Healthcare, Malvern, PA, USA), 
FASTlab/TRACERlab (GE Healthcare, Wauwatosa, WI, USA), FDG-Plus 
Synthesizer/Modular-Lab (Eckert & Ziegler, Valencia, CA, USA), Synthera (IBA Molecular, 
Dulles, VA, USA), and NanoTek (Advion, Ithaca, NY, USA). All these modules provide the 
reproducibility and acceptable yield of 
18
F-FDG, even if design concepts are slightly 
different. The design concept of Explora FDG4, TRACERlab, and FDG-Plus Synthesizer are 
the integration of equipment which is more close to the pioneer prototype made by 
Merrifield and Stewart(53). There are commercially available 
18
F-FDG kits for these 
modules include syringes, vials, tubes, needles, and chemicals. Other modules, like 
FASTlab, Synthera, and NanoTek, integrate functions of these items into a single-use 
cassette or a microfluidic chip in order to increase the yield of 
18
F-FDG and minimize the 
size of the module. Modular-Lab is a fully user-defined system which is assembled by 
various valves, sensors and other equipment, and this type of design can increase its 
flexibility for different methods of radiosynthesis. Besides modules for synthesis of 
18
F-
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FDG by nucleophilic fluorination, these companies developed other modules and kits for 
electrophilic fluorination, and other radioisotopes, such as 
11
C, 
13
N, 
15
O, and 
68
Ga. These 
commercial automated synthesizers are listed in Table 1.4.  
 
 
Figure 1.6 Images of common commercialized synthesis modules. 1: Explora FDG4; 
2:Fastlab;  3:FDG-Plus; 4:Modular-lab; 5:NanoTek; 6:Synthera; 7: TRACERlab FX C Pro; 
8: TRACERlab FX E Pro; 9: TRACERlab FX N Pro. 
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Table 1.4 Common Commercialized Automated Radiopharmaceuticals Synthesizer 
Module Manufacture Comments Radiopharmaceuticals 
FASTlab GE Disposable cassette/ 
No HPLC integrated 
Size: 41cmx44cmx51 
cm (W x H x L) 
18
F-FDG 
18
F-NaF 
18
F-FMISO 
18
F-FLT 
TRACERlab FX N Pro GE Production of [
18
F] 
tracers via nucleophilic 
substitution with [
18
F] 
F- Fluoride trapped 
from [
18
O] water/HPLC 
integrated 
Size: 49 cm x 48 cm x 
50 cm (W x H x L) 
18
F-FTHA 
18
F-Fluoromisonidazole 
18
F-Methylbenperidol 
18
F-Methylspiperone 
18
F-Fluorostradiol 
18
F-Altanserine 
18
F-FLT 
18
F-FDG 
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TRACERlab FX E Pro GE Production of general 
[
18
F] tracers via 
electrophilic 
substitution with [
18
F] 
Fluorine in the form of 
F2/ HPLC integrated 
Size: 29 cm x 48 cm x 
35.5cm (W x H x L) 
18
F-FDOPA 
18
F-FLT 
18
F-Fluorouracil 
TRACERlab FX C Pro GE Production of [
11
C] 
labeled tracers by 
methylation reactions 
using methyl iodide or 
methyl triflate 
produced from either 
carbon dioxide or 
methane/HPLC 
integrated 
Size: 50cm x 48 cm x 
45cm (W x H x L) 
11
C-Raclopride 
11
C-Metahydroxyephedrine 
11
C-Methylspiperone 
11
C-Methionine 
11
C-Acetate 
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Explora FDG4 Siemens Disposable cassette 
/No HPLC integrated 
Size: 61cm x 14 cm x 
36cm (W x H x L) 
18
F-FDG 
FDG-Plus Eckert & 
Ziegler 
No HPLC integrated 
Size: 45cm x 25 cm x 
50cm (W x H x L) 
18
F-FDG 
18
F-NaF 
18
F-FMISO 
18
F-FLT 
Modular-lab 
 
Eckert & 
Ziegler 
Integrated with various 
types of actuators, and 
sensors.   
68
Ga-Tracers 
18
F-Tracers 
11
C-Tracers 
Synthera IBA 
Molecular 
Disposable cassette 
(Integrated Fluidic 
Processor) 
/ No HPLC integrated 
Size: 17cm x 29 cm x 
18
F-FDG 
18
F-NaF 
18
F-FMISO 
18
F-FLT
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28.5cm (W x H x L) 
NanoTek Advion Microreactors & HPLC 
integrated 
18
F-Fallypride 
18
F-FDG 
11
C-CO 
 
However, the major goal of these modules is for clinical usage. Therefore, 
scientists have to modify the commercialized modules or to build their own modules for 
production of specific radiopharmaceuticals (63-77).  
In the trend of industry, the basic purpose of automated production is to provide 
massive and quality product to customers, and the development of automated 
production is the result of demand for applications. In addition, automated synthesis 
modules are housed in a lead-shield chamber which is called “hot cell”, and hot cell can 
reduce the unnecessary radiation exposure to employees. Considering the space usage 
in a hot cell, the design of appearance of current commercialized modules has a 
tendency to compact module, and this feature can maximize the utilization of hot cell 
space. 
1.5 Scope of the dissertation 
The role of automated radiopharmaceuticals synthesis modules in clinics is to 
reduce the radiation exposure during the production of radiopharmaceuticals and 
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provide a consistant amount of radiopharmaceuticals with quality control and quality 
assurance. In order to achieve the goal, the hardware and software designs have to be 
optimized for the specific synthesis method, and the size of the module can be housed 
in the hot cell. In research field, radiochemists want to synthesize novel 
radiopharmaceuticals for different applications, and to optimize the synthesis methods 
for good quality radiopharmaceuticals. Therefore, numerous ideas for 
radiopharmaceuticals synthesis are practiced for these purposes. However, the features 
of clinical automated synthesis modules limit possibilities for performing these ideas.  
In order to bridge the gap between the research interests and clinical demands, a 
multi-purpose automated synthesis module for production of novel PET 
radiopharmaceuticals is needed. Our hypothesis is that we can design an automated 
synthesis module, the hardware configuration and the software design can transform 
the manual chemical reaction processes into automated synthesis steps, which may 
allow users to synthesize three different PET pharmaceuticals with quality control by 
organic or metallic chemical reactions. Three specific aims are addressed to test this 
hypothesis.  
 
Specific Aim 1: To design, assemble and test the hardware of this module for 
transforming manual synthesis processes into automated steps.   
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Specific Aim 2: To develop the software for creating synthesis receipts and recording 
data, including time, temperature, and flow rate.   
Specific Aim 3: To validate the automated synthesis module by producing three 
different PET radiopharmaceuticals gallium-68-ethylenedicysteine-glucosamine (
68
Ga-
GaECG ), [
18
F]fluoropropyl-α-methyltyrosine (
18
F-FPAMT), and [
18
F]fluoro-5-
propylhydroxy tryptophan
 
(
18
F-FHTP), with high radiochemical purity (>90%), acceptable 
pH range (pH=4.5~8.3). 
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2 Chapter 2 Hardware design and Setup 
2.1 Introduction of hardware design 
Traditionally, chemists used graduated cylinders, flasks, beakers, hot plates, 
thermometers, and other material to complete chemical reactions. Several reaction 
steps are involved to compose a synthesis method. In order to design the hardware of 
this module, we spitted each chemical reaction into several simple actions. Each action 
is controlled by appropriate sensors and actuators(78). Through the customized user-
interface and other equipment, users could control sensors and actuators to complete 
the synthesis.  
There are three different levels of the hardware design for this automated 
synthesis module. First, we defined the basic actions of this automated synthesis 
module. Secondly, we searched appropriate electrical and mechanical components to 
complete these basic actions, designed the customized circuit board, and drawed the 
blueprint of this automated module. Lastly, after completing physical appearance of this 
module, we assembled each component to complete the hardware of this module.     
 
2.2 Basic actions for chemical reactions 
We defined five actions, such as add, purge, heat, transfer, and mix. The definition 
of “add” is “Inject the solution to the reaction vial”. The definition of “Purge” is 
“Remove the residual solution from the channels to the reaction vial”. The definition of 
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“Heat” is “Heat the reaction vial at the specific temperature in a short time”. The 
definition of “Transfer” is “Transfer the solution in the reaction vial to another reaction 
vial”. The definition of “Mix” is “Use bubbles to mix the solution inside the reaction vial”. 
 
2.3 Selection of hardware components for the basic actions 
Based on the definition of basic actions, we found appropriate components to 
complete the chemicals reactions. In addition, these components are capable of 
production of various radiopharmaceuticals in the extreme conditions, such as extra 
small volumes, higher temperature, high pressure, and radiation exposure.   
“Add”  
By its definition, the module can transfer certain quantities of chemicals into the 
reaction vials. In order to control this action, we designed a customized syringe pump by 
using the stepper motor. Several customized syringe pumps, and different types of 
valves are used to integrate this action into the multi-purposes synthesis,.       
“Purge” 
By its definition, the module can purge the residual solution from the flow 
channel to the reaction vial. We used nitrogen gas as the pressure source to transfer the 
residual solutions, and a mass flow controller to maintain the nitrogen pressure for 
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processing this procedure. Concerning integration this action into the multi-purposes 
synthesis, different types of valves for specifying “purge” affected zone were employed.  
“Heat” 
Among many options of heating method, we selected the infrared heater due to 
its rapid heating process. The functions of heating in chemical reactions usually are to 
speed up the process of the chemical reactions or to evaporate solvents. Therefore, a 
small vacuum pump is used to increase the evaporation rate. Concerning integration 
this action into the multi-purposes synthesis, the infrared heater is mounted on the 
plate which is driven by the stepper motor, and different types of valves can provide the 
pressure balance inside the module. Consequently, “heat” can work on different 
reaction vials.  
“Transfer” 
The definition is very similar between “add” and “transfer”. The difference 
between these two actions is that “Transfer” use compressed nitrogen gas as the power 
source of transferring. Concerning integration this action into the multi-purposes 
synthesis, we used different types of valves to specify the source and the destination of 
“Transfer”.    
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“Mix” 
We used a vacuum pump to cause the negative pressure inside the reaction vial. 
Therefore, air can enter the reaction vial, and become bubbles which can mix the 
solution to increase the chemical reaction rate.       
All these basic functions are operated by electrical or mechanical components. In 
order to control these components, a control system is used to exchange single 
between these components, and a power supply is needed to provide adequate power 
to these components. In addition, this control system allows us to design the 
customized user interface by its operational software. Besides a control system and a 
power supply, a customized circuit board is designed to manage signal and power for 
each component.  
Our multi-purposes automated synthesis module consists of two parts, the 
control box and the synthesizer. The main components of this control box are the two 
power supplies, the one solid state power controller, and the control system. One 
power supply can provide 24V/5A (PS-12024, Altech Corp., Flemington, NJ, USA), and 
another power supply can provide 12V/10A (PS-12012, Altech Corp., Flemington, NJ, 
USA). Both power supplies are connected to the circuit protection devices (Altech Corp., 
Flemington, NJ, USA). The solid state power controller (DIN-A-MITE Style C, Watlow, St. 
Louis, Missouri, USA) provides voltage to the infrared heater. The control system 
consists of five parts, the ethernet/RS232 interface with 4 slot backplane module (cFP-
1804, National Instruments, Austin, TX, USA), two digital output modules (cFP-DO-401, 
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National Instruments, Austin, TX, USA), and two analog input/output modules (cFP-AIO-
600, National Instruments, Austin, TX, USA). These digital and analog modules are 
connected with 4-slot ethernet/serial interface module, and the customized circuit 
board of the synthesizer. Users can control the synthesizer through ethernet by 
connecting the network line between the laptop to the 4-slot ethernet/serial interface 
module. The layout of the control box is shown in Figure 2.1, and the picture of the 
control box is shown in Figure 2.2.  
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Figure 2.1 The layout of control box 
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Figure 2.2 The picture of the control box 
The synthesizer consists of one mass flow controller (FMA5508, Omega 
Engineering, Inc., Stamford, CT, USA), one customized circuit board, one USB to RS485 
converter (USB485, RMS Technologies, Carson City, NV, USA), one infrared heater 
(Model 5306, RESEARCH INC., Eden Prairie, NM, USA), four radiation sensors (Si 
photodiode S8559, Hamamatsu Photonics K.K., Hamamatsu City, Japan), two 
temperature sensors (RTD-860, Omega Engineering, Inc., Stamford, CT, USA), one 
vacuum pump (C117H-12, Hargraves Technology Corporation, Mooresville, NC, USA), 
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two 6-way rotary valves (C65Z-3186I, Valco Instruments Co. Inc., Houston, TX, USA), 
three 4-way rotary valves (C65Z-3186I, Valco Instruments Co. Inc., Houston, TX, USA), 
five 3-way solenoid valves (LFRX0500600BE, The Lee Company, Westbrook, CT, USA), 
five two-way solenoid valves (6126, Bürkert, Charlotte, NC, USA), seven stepper motors 
(PK223PA-SG18, Oriental Motor, Basingstoke, UK), seven stepper motor controllers 
(R256, RMS Technologies, Carson City, NV, USA), and various types of HPLC fittings 
(Valco Instruments Co. Inc., Houston, TX, USA). The figure 2.3 shows the layout of the 
customized circuit board with joint indicators of the components in the synthesizer. The 
figure 2.4 is the appearance design drawings of this synthesizer, the top view, the front 
view, and the side view. The figure 2.5 is the detail appearance design drawing of this 
synthesizer. The figure 2.6 is the front view picture of the synthesizer.   
2.4 Validation of hardware components of this module 
After assembling the module, different validation methods were practiced in 
different components. Voltage transferred from the control box can test the function of 
valves, and current transferred from the control box can test the function of IR heater. 
Because the stepper motor connected to the module through USB, the hyperterminal 
was used to test the function of stepper motors, including forward, backward, and 
safety issue.  
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Figure 2.3 The layout of the customized circuit board ?????? 
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Figure 2.4 The appearance design drawing of this synthesizer 
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??Figure 2.5 The detail appearance design drawing of this synthesizer: Front View 
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?? 
Figure 2.6The front view picture of the synthesizer 
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3 Chapter 3 Software Design and Setup 
In the chapter 2, appropriate components are selected to provide essential 
functions for this automated synthesis module. In this chapter, procedures to set up the 
connection between the synthesizer and the laptop through the control module, the 
controlling principle for each component of this automated synthesis module, the 
important operational codes, and the operational methods of the user interface are 
discribed. The software of this multi-purpose automated synthesis is developed by 
LabVIEW 2009 which is a visual programming language of National Instruments for 
programmable logic controller, and this program provide the software debug. The basic 
program of LabVIEW 2009 is called virtual instrument (VI).  
 
3.1 Steps for initializing the connection between hardware and software  
After connecting the ethernet cable from the control box to the laptop, the 
software, Measurement & Automation Explorer (National Instruments, Austin, TX, USA) 
was initialized. Through this software, a physical IP address for NI cFP-1804 in the 
control box (Figure 3.1) can be assigned. Then, each channel of input/output modules 
can be controlled. By turning on/off the signal of these modules (Figure 3.2), the basic 
operation of each component, and debug the connections of hardware components can 
be tested.  
 
37 
 
 
Figure 3.1 IP Assignment of the control box through MAX 
 
Figure 3.2 Controllable channels in cFP-DO-401 module 
3.2 Overall scheme of the software design  
Based on the definition of the basic actions of this synthesizer in chapter 2, these 
functions allow to complete the automated synthesis process. In addition to prove the 
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concept of multi-purpose automated synthesis comprehensively, there are more 
features of this customized operational software, such as user-friendliness, safety, and 
modifiability. 
3.2.1 User-friendliness 
The software user interface is performed in a graphical user interface (GUI) 
which can be easily utilized and understood for laboratory personnel with typical 
training and experience in this field.   
 
3.2.2 Safety 
The software is able to check the connection between the components, the 
control box and the laptop. Flow pressure and heating temperature are restricted in a 
range for safety operation. In addition, a user can pause or stop the current step during 
the emergency. After trouble shooting, the user can resume the synthesis process.  
3.2.3 Modifiability 
The parameters in basic actions and the total synthesis recipe will be modifiable 
based on the user’s demands without difficulty or confusion. 
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3.3 The controlling principle for each component of this automated synthesis 
module 
Stepper motors are controlled by HyperTerminal codes through the usb to rs485 
converter, and other hardware components are controlled by current or voltage 
changes in each channel of NI modules. In LabVIEW 2009, “global variable” is used to 
describe these changes which can indicate the current property of the hardware 
component. I have created “cFP comm handler” VI to control or receive each channel of 
analog/digital signal modules.  
3.3.1 Solenoid Valve 
Five different channels in the cFP-DO-401 module can deliver 12 V to trigger five 
2-way valves individually; other five channels in the same module can deliver 12 V to 
trigger five 3-way valves individually.  
3.3.2 Rotary Valve 
Each rotary valve is controlled by two digital channels in the other cFP-DO-401 
module. Triggering one channel is to move the rotor back to the default position of the 
rotary valve, and triggering another channel is to moves the rotor in a counterclockwise 
direction to next position. If the default position of 6-way rotary valve 1 is position 1, it 
would have to trigger 3 times for switch the position 1 of the rotary valve to position 4. 
If it is necessary to switch the rotor from position 4 to position 2, it would have to 
trigger 4 times.  In order to complete this task, I created the “rotary position calculator” 
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VI. In this VI, each rotary valve has its own case structure from the commands of 
Labview 2009. Here, the rotary number 1 is selected as a working example. After 
sending new position of the rotary valve 1, there will be two conditions. If the new 
position number is more than or equal to the previous position number, the calculation 
shows the Figure 3.3. If the new position number is less than the previous position 
number, the calculation shows in the Figure 3.4. After calculation, these information 
including active rotary valves, and number of triggers, are sent to “execution” VI. 
 
Figure 3.3 “rotary position calculator” VI_ Case 1 
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Figure 3.4 “rotary position calculator” VI_ Case 2 
 
3.3.3 Mass Flow Controller 
The functions of this mass flow controller are to monitor and control nitrogen 
flow rate by one input channel and one output channel in the cFP-AIO-600 module, 
respectively. “cFP comm handler” VI can provide two functions, “I read” and “I set”, 
which are detailed in section 3.4.1.. Determined by the calibration chart from the 
manufacture, we can know the relationship between current and the flow rate.  
3.3.4 Infrared Heater 
The infrared heater is controlled by one analog input channel in the cFP-AIO-600 
module, and “I set” in the “cFP common handler” VI can be used to set different current 
for controlling heating rate. In chemical reactions, an ideal heater should provide fast 
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heating, but doesn’t have the occurrence of overheating. In order to avoid overheating, 
I created the proportional-integral-derivative (PID) controller which can send different 
current based on the temperature in the reaction vial.  
3.3.5 Temperature Sensor & Radiation Sensor  
Each sensor is able to send current to one analog input in the cFP-AIO-600 module. In 
order to calculate the relationship between temperature in the reaction vial and current, 
after infrared heater turned on, I set various currents and recorded different 
temperature in the vials which is measured by a thermo couple thermometer. Then, I 
have the relationship equation which is established for temperature monitoring (Figure 
3.5).   
 
 
 
 
 
Figure 3.5 The relationship of measured voltage and vial temperature 
The radiation sensor uses a small CsI scintillator to detect X-ray energy, and its 
size is very small. Therefore, it can’t be used as real radiation counter. However, it can 
(V-Toffset)*Tgain=Temperature 
*T1offset=1.1239, T1gain=475.05 
* T2offset=1.1178, T2gain=430.00 
T1: Temperature in Vial 1 
T2: Temperature in Vial 2 
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provide the relative information of radiation which can indicate the radiation solution in 
what location.  
3.3.6 Vacuum Pump 
The vacuum pump is controlled by one voltage output channel in the cFP-DO-
401 module.  
3.3.7 Stepper Motor  
Through an usb to rs485 converter, these stepper motor controllers can connect 
to PC or laptop. Instead of creating “global variable”, I have to use NI Virtual Instrument 
Software Architecture (NI VISA) to communicate with these controllers by 
HyperTerminal codes. 
 
 
 
3.4 Important operational VIs 
In previous sections, the relationship between hardware components of the 
synthesizer, the modules in the control box, and some Vis were described. In this 
section, the functions of important operational VIs in details are described.   
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3.4.1 cFP comm handler VI 
This VI can send and receive the signal between NI modules and the hardware 
components. There are six functions in this VI, “digital set all”, “digital set”, “set rov”, “I 
set”, “I read”, and “V16 read”.  
3.4.1.1  “digital set all”  
 
Figure 3.6 The code of ““digital set all” of “cFP comm handler” VI 
When the software initialize, this default function of this VI (figure can set 
default value to each channel in the second digital module (cFP-DO-401).  
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3.4.1.2  “digital set”  
 
Figure 3.7 The code of “digital set” of “cFP comm handler” VI for digital module 1 
 
Figure 3.8 The code of “digital set” of “cFP comm handler” VI for digital module 2 
This function is to send the signal to the assigned channel of the specific digital 
module. In this software, each module has 16 channels. I name the channels in module 
1 from number 1 to number 16 (Figure 3.7), and the channels in module 2 from number 
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17 to number 32 (Figure 3.8) are named. The function “digital set” is sufficient for 
voltage-actived components, such as solenoid valves, and the vacuum pump. 
 
3.4.1.3  “set rov”  
 
Figure 3.9 The code of “set rov” of “cFP comm handler” VI 
The operation method of the rotary valve is its rotor can move to next position 
when receiving two triggers, one is to turn on the channel, and another is to turn off the 
channel. The digital module and the rotary valve need a short time to process between 
two consecutive triggers. Therefore, I put two delays in this function to provide a 
sufficient time period for the communication of the rotary valve controller and the 
digital module.   
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3.4.1.4  “I set” 
 
Figure 3.10 The code of “I set” of “cFP comm handler” VI 
The function “I set” can send various current through the analog module to 
control the mass flow controller and the infrared heater. Because these components 
only work properly in a certain range of current, I put a logic option to control the 
current under the safe range which is between 3.5 to 20 mA. 
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3.4.1.5 “I read” 
 
Figure 3.11 The code of “I read” of “cFP comm handler” VI 
The function “I read” is to receive the data from the radiation sensors and 
temperature sensors through the analog module.  
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3.4.1.6  “V16 read” 
 
Figure 3.12 The code of “V16 read” of “cFP comm handler” VI 
This function “V16 read” is to check the connection status of the digital modules, 
and it only works when initialing the software. 
3.4.2 Execution VI 
We can use the previous VI to control the components or receive the signal from 
sensors. “Execution” VI is to execute the combination of these commands to complete 
one single basic function. Each basic functions includes several parameters, such as 
valves, vacuum, syringe, injection volume, injection rate, N2 flow rate, heating 
temperature, rotary valve position, and heater position. Depended on the features of 
the basic function, assigned parameters are executed in the sequence in this VI. First, 
the status of each valve is determined (Figure3.13). 
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Figure 3.13 “Execution” VI_Step 1 
 
 After that, the position of each rotary valve is determined (Figure 3.14). 
Figure 3.14 “Execution” VI_Step 2 
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Right now, the flow path is set up. The third step can turn on mass flow controller to 
allow N2 flow into this synthesizer for transfer solution to another location (Figure 3.15). 
 
Figure 3.15 “Execution” VI_Step 3 
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The fourth step can control the stepper motor to inject the chemical in the different 
speed (Figure 3.16). 
 
Figure 3.16 “Execution” VI_Step 4 
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The last step can control the position of the heater and adjust the heating temperature 
(Figure 3.17). 
 
Figure 3.17 “Execution” VI_Step 5 
After the duration ends, there are another sequence of commends which can set 
components to the default condition, except stepper motors. The default condition of 
flow path is suitable to release the pressure in the vials and channels, and can avoid the 
unexpected damage.  
3.5 Operation of Software  
3.5.1 Starting the Application 
To start up the application, the user should double-click the customized icon on 
your desktop that was placed there by the installer.  
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3.5.2 Panels of the Application Window 
3.5.2.1 Main control panel 
 
Figure 3.18 Main control panel 
This is the overview of the main control panel (Figure 3.18). This panel is divided 
by three parts, and the function of each part is described in the following paragraph. 
Every time the user begins a new synthesis recipe, he should click the file button in the 
upper left of this panel, and choose the reagent setup function. 
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Figure 3.19 Reagent setup panel and its correspondent components in the synthesizer 
In the reagent setup (figure 3.19), the user can type the information of syringes 
in the synthesizer which includes the chemical name, and its initial volume. Based on 
different synthesis recipes, there would be different reagent setup. The user also can 
create new a reagent setup, open a previous reagent setup, edit the current reagent 
setup, or save a new reagent setup via this user interface. Without this step, the 
automated synthesis can’t process correctly. 
Main control panel _ part 1 
 
Figure 3.20 Main control panel _ part 1 
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This is the general information of this module, including its temporary logo, 
location, facility.  
Main control panel _ part 2 
 
Figure 3.21 Main Control Panel _ Part 2 
This upper part of this picture is a dialogue window, and the user can know the 
current process in this synthesizer. The middle left part of this picture is the information 
of total synthesis process, including the step of process, the total synthesis time, and the 
remaining time. The middle right part of this picture can allow users to choose the 
recipe by clicking the file icon. Under the recipe dialogue, it’s the user-defined sample 
information, and the user-defined number of batch. The bottom part of this picture are 
the action buttons, including Start, Pause, Abort, Home Syringes, Home Valves, and 
Automatic/Single step. Once the recipe and its parameters are determined, user should 
click “Home Syringes”, and “Home Valves” buttons to set hardware into the default 
condition. After that, depending on the demands, user can choose run this recipe 
automatically or step by step. Right now, the user can click “Start” button to begin the 
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synthesis process. During the process, the user can click “Pause” or “Abort” to stop the 
current process or terminate the synthesis.  
 
Main control panel _ part 3 
 
Figure 3.22 Main control panel _ part 3 
The button of the main control panel can show the each process of this recipe, 
allow users to edit the recipe, and show the sensor log file.  After the user click “Edit 
Recipe…” button, the user can edit the recipe in the recipe editor.  
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3.5.2.2 Recipe edit panel 
 
Figure 3.23 Recipe edit panel 
The top window shows the current recipe, and the user can change the recipe by 
clicking “file” icon. The left window shows the five basic function of this automated 
synthesizer. The middle window shows the whole process of the current recipe. The left 
parts are the icons, which can save the recipe, edit the step, delete step, simulate the 
recipe, close the recipe editor, and home syringes.  
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Figure 3.24 “Add” panel and its correspondent components 
This basic function, “add” is to transfer the reagent from the syringe to the vial 
with different flow rates. In this user interface, the user can control four different 
parameter, injection volume, reagent source, destination, and injection speed. The 
injection volume and regents would be restricted by initial setting in the reagent setup. 
The displayed number in the reagent window indicates the actual syringe in this 
synthesizer. The injection speed is between 0.01 to 0.1 (ml/sec). Based on the speed, 
the duration can be calculated in this panel.  
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Figure 3.25 “Purge” panel and its correspondent components 
  After the reagent injected into the vial by the syringe, there are some residual 
solution in the flow channel. The function, “Purge”, can use N2 flow in different speed to 
take these residuals into the vial. In this user interface, the user can control four 
parameters, reagent source, destination, duration, and flow rate. The options of the 
reagent and the destination in this function are identical to the “add” function. The user 
can set the suitable duration of “purge”, and different N2 flow rate, such as high (200 
ml/sec), med-high (180 ml/sec), med(140 ml/sec), med-low(100 ml/sec), and low(50 
ml/sec).  
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Figure 3.26 “Transfer” panel and its correspondent components 
Based on the source and the destination, there are three different options of 
“transfer” step, from injection port to vial 1, from vial 1 to vial 2, and from vial 2 to 
product vial. The user can optimize the performance of “transfer” by changing the 
parameters, duration and flow rate.  
         
Figure 3.27 “Heat” panel and its correspondent components 
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There are four parameters of this “heat” function, heating temperature, heated 
vial, heating duration and addition states. Currently, the working temperature is 
adjusted from 65°C to 85°C. Two reaction vials, Vial 1 and Vial 2, can be heated by the 
IR-heater which is installed on the horizontal stepper motor, and this stepper motor can 
move this IR-heater to different locations on this synthesizer. Based on the different 
conditions of reactions, users can change the heating duration for the optimization of 
the end of synthesis radiation yield. There are three different conditions of “state”, 
vacuum, vent, and off. The “vacuum” can turn the vacuum pump to evaporate the 
solvents. The “vent” can cause the one channel of the vial open to the outside, and this 
aspect is used to maintain the pressure balance inside the vial when the vial is heated at 
high temperature or for longer heating duration. The “off” can maintain the solvent 
volume inside the vial when the vial is under heating.  
 
Figure 3.28 “Mix” panel 
There are three parameters in “Mix” function, vial, flow rate, and duration. The 
user can choose the selected vial with different flow rates and different durations for 
optimization of the synthesis process.  
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3.5.2.3 Trending panel 
 
Figure 3.29 Treading panel 
The Trending panel displays real-time graphic data from the radiation sensors, 
vacuum pump pressure, nitrogen flow, and reaction vial temperature, and these data 
are sampled in every five seconds. When the user begin the automated synthesis, these 
information could automated saved into an excel file.  
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4 Chapter 4 Validation of this multi-purpose synthesis module 
4.1 Overview of this chapter 
Molecular imaging can detect the cellular changes before these changes cause 
malformed tissue structures. Furthermore, molecular imaging can provide the 
information about not only tumor localization, but also tumor characterization (79). The 
most common radiotracer for staging tumors is 
18
F-FDG (80). Diagnosis of cancers by 
18
F-
FDG PET is based on the observation on the difference of 
18
F-FDG accumulation 
between normal and abnormal tissues caused by irregular glucose metabolism including 
overexpression of glucose transporter 1 and/or enhanced type 2 hexokinase activities 
(81). However, 
18
F-FDG PET has several limitations that give rise to false 
positive/negative results. Therefore, it is amenable to develop different radiotracers as 
alternatives for better differentiation in tumor imaging. Overexpression of glucose 
transporter 1 glycosylation and large amino transporter 1 are discovered in various 
progressive cancers (82, 83). In this study, a glucose analog, glucosamine, and large 
amino acids, alpha-methyl-p-tyrosine and tryptophan, are selected to be radiolabeled.   
 
The hardware and the software of this automated multi-purpose synthesis module 
were described in previous chapters. In this chapter, the manual synthesis of reference 
compounds of these three different radiopharmaceuticals, 
68
Ga-ECG, 
18
F-FPAMT, and 
18
F-FTP, were determined and qualitative analyses of reference compounds were 
confirmed. After that, manual radiosynthesis recipes of the radiopharmaceuticals were 
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established, and the radiochemical purity were determined. Then, this automated multi-
purpose synthesis module was validated by production of these three 
radiopharmaceuticals.  
 
4.2 Synthesis of 
68/69
Ga-ECG 
4.2.1 Synthesis of ECG  
The total synthesis scheme of 
68/69
Ga-ECG is shown in Figure 4.1. To a solution of 
thiazolidine-4-carboxylic acid (T) (2.6 g, 0.02 mol) in DMF (20 mL) and 5.0 mL 
trimethylamine, 1-hydroxybenzotriazole hydrate (2.7 g, 0.02 mol) was added. After 
30 min, 1,3,4,6-tetra-O-acetyl-2-amino--D-glucopyranose hydrochloride (G-(Ac)4) (7.7 g, 
0.02 mol), N,N-di-cyclohexylcarbodiimide (DCC, 4.2 g, 0.02 mol), and 4-
dimethylaminopyridine (DMAP, 1.2 g, 0.01 mol) were added to the mixture and stirred 
for overnight at room temperature. The solution was evaporated to dryness at high 
vacuum. Dichloromethane (50 mL) was added to the residual and kept at 4°C for 
overnight, then filtered. The product was purified with silica gel by eluting with 
CH2Cl2/MeOH (95:5, v/v) to yield white product T-G-(Ac)4 4.08 g (44.2%). NMR and mass 
spectrometry were used to confirm the structure of T-G-(Ac)4. Sodium was added piece 
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by piece to a solution of T-G-(Ac)4 (4.08 g, 8.8 mmol) in liquid ammonia (170 g). The 
color of the solution was slowly changed to dark blue. After 30 minutes, a little of 
ammonium chloride was added. The liquid ammonia was removed by reduced pressure. 
The residual solid was triturated with methanol (100 mL). The solid was then filtered 
and washed with additional methanol (50 mL) to yield crude product 4.16 g. To obtain 
analytical pure ethylenedicysteine-glucosamine (ECG), the crude product (0.1 g) was 
dissolved in HCl (0.1 N, 1.0 mL) and purified with a sephadex column by eluting with H2O. 
The aqueous fractions were combined and lyophilized to yield ECG (0.029 g, 46.7%). 
HPLC shows that purity is over 82%. NMR and HPLC were used to confirm the structure 
and the purity of ECG. HPLC of cold ECG was in Figure 4.2. 1H NMR (D2O, �): 3.15–3.20 
(m, 4H), 3.78–4.05 (m, 6H), 4.08–4.15 (m, 8H), 4.2-4.3 (d, 2H), 4.68–4.73 (d, 2H), 5.19–
5.21 (d, 2H).  
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Figure 4.1 Synthesis scheme of ECG 
 
Figure 4.2 HPLC analysis of ECG 
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4.2.2 Synthesis of 
69
Ga-ECG 
69
GaCl3 (20 mg, 0.11mmol) in H2O (0.2 mL) was added to a solution of ECG (60mg, 
0.1mmol) in H2O (0.5 mL). The pH value was adjusted to 4-5 with NaOH (0.1N, 50 µl). 
The solution was heated for 30 min at 60°C. The product was purified by a sephadex 
column eluting with H2O to yield 
69
Ga-ECG. After lyophilization, 
69
Ga-ECG was obtained 
as white solid (52mg, 78.1%). NMR, and HPLC were used to confirm the structure and 
the purity of 
69
Ga-ECG. NMR of cold 
69
Ga-ECG was in Figure 4.3. 1H NMR (D2O, �): 2.94–
3.38 (m, 8H), 3.43–3.65 (m, 4H), 3.50–3.80 (m, 10H), 3.92–4.02 (t, 2H), 4.23–4.34 (d, 2H), 
5.15–5.34 (d, 2H).  
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Figure 4.3 HPLC analysis of 
69
Ga-ECG 
 
4.2.3 Manually synthesis of 
68
Ga-ECG 
68
GaCl3 was obtained from a 
68
Ge/
68
Ga generator (Eckert Ziegler, Valencia, CA) 
eluted with 0.1 N HCl. 
68
GaCl3 (120 �L, 300 �Ci) was added to the solution of ECG 
(1.2 mg) in H2O (0.1 mL), and pH value was adjusted to 4-5 with NaHCO3 (40 �L, 0.1 N). 
The solution was heated at 65°C for 15 min. Radio-TLC analysis of the purity of 
68
Ga-ECG 
was > 90% (Figure 4.3). 
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Figure 4.4 Radio-TLC analysis
 
of 
68
Ga-ECG by manual synthesis 
 
 
4.2.4 Automated Synthesis method of 
68
Ga-ECG 
ECG (1.3mg) was preload into the reaction vial 1 (RV1) of the automated module, 
and 
68
GaCl3 (1mL, 5.40 mCi) was loaded into the RV1 from manual injection port. Then, 
the solution of NaHCO3 (200 µL) injected into the reaction vial 1 from the injection panel, 
and pH value was adjusted to 4-5. After that, the RV1 was heated at 70°C for 15 minutes. 
The final step was to transfer the solution in the RV1 to the final product vial. The 
automated recipe of 
68
Ga-ECG synthesis is shown in Figure 4.4.  Radio-TLC analysis of 
the purity of 
68
Ga-ECG was > 90% (Figure 4.5).  
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Figure 4.5 Automated synthesis recipe of 
68
Ga-ECG 
  
 
Figure 4.6 Radio-TLC analysis
 
of 
68
Ga-ECG by automated synthesis 
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4.3 Synthesis of 
18/19
F-FPAMT 
4.3.1 Synthesis method of 
19
F-FPAMT  
N-t-butoxycarbonyl-O-[3-hydroxypropyl]-α-methyl tyrosine ethyl ester (490 mg; 
1.28 mmol) in anhydrous pyridine (32 mL) was cooled to 0°C. Paratoluenesulfonyl 
chloride (1015 mg; 5.32 mmol) was added to this solution, and the solution was stirred 
for 30 min. After it filtered, the filtrate was poured into iced water and extracted with 
diethyl ether. The ethereal solvent was washed with 30 mL of hydrochloric acid and 
water (1 : 1, v/v) to remove pyridine, and the solvent was dried over anhydrous MgSO4. 
After filtration and solvent evaporation, N-t-butoxycarbonyl-O-[3-tosylpropyl]-α-methyl 
tyrosine ethyl ester (Tso-PAMT/BOC/Ester) was purified by column chromatography 
using a silica gel column and eluted with hexane and ethyl acetate (2 : 1, v/v) to yield 
430 mg (62.5%). NMR, and Mass Spectrum were used to confirm the structure and the 
purity of Tso-PAMT/BOC/Ester shown in Figure 4.6 and Figure 4.7. 
1
H NMR (CDCl3) 
δ=7.78 (d, 2H, J=8.10 Hz), 7.28 (d, 2H, J=5.70 Hz),  7.00 (d, 2H, J=8.70), 6.70 (D, 2H, 
J=8.70 ), 4.24 (dd, 2H, J=5.70), 4.17 (t, 2H, J=21.3), 3.96 (t, 2H, J= 11.70), 3.17 (d, 2H, 
J=13.8), 2.41 (s, 3H), 2.13 (dd, H, J=12.00). 1.56 (s, 3H), 1.49 (s , 9H) 1.33, (t, 3H, J=21.9 
Hz) ppm. 
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Figure 4.7 NMR of Tso-PAMT/BOC/Ester 
 
Figure 4.8 Mass spectrum of Tso-PAMT/BOC/Ester 
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Synthesis of 
19
F-FPAMT was carried out by three steps (Figure 4.8). The 
displacement reaction is the first step. Kryptofix 222 (253.9 mg; 0.67 mmol) and K
19
F 
(40.5 mg; 0.69 mmol) were added to a vial containing N-t-butoxycarbonyl-O-[3-
tosylpropyl]-α-methyl tyrosine ethyl ester (compound 1; 390 mg; 0.75 mmol) in 
acetonitrile (1 mL). The reaction vial was heated under reflux at 90°C for 40 min. After 
heating, the solution was evaporated to dryness. The mixture was reconstituted in ethyl 
acetate (0.5 mL). N-t-butoxycarbonyl-O-[3-
19
F-fluoropropyl]-α-methyl tyrosine ethyl 
ester (compound 2) was purified by column chromatography using a silica gel column 
and eluted with hexane and ethyl acetate (4 : 1, v/v) to yield 120.0 mg of the compound. 
The second step was to deprotect butoxycarbonyl (BOC), and the third step was to 
remove ethyl ester groups. O-[3-
19
F-fluoropropyl]-α-methyl tyrosine ethyl ester 
(compound 3) was synthesized by reacting N-t-butoxycarbonyl-O-[3-
19
F-fluoropropyl]-α-
methyl tyrosine ethyl ester (compound 2; 82.3 mg; 0.30 mmol) with trifluoroacetate 
(0.7 mL) in dichloromethane (2.0 mL) at room temperature for 50 min. After the solvent 
was evaporated to dryness, sodium hydroxide (1 N; 1.0 mL) in methanol (1.0 mL) was 
added, and the mixture was heated at 90°C for 15 min to remove ethyl ester group. The 
mixture was passed through a 0.22 μM filter to yield 
19
F-FPAMT (compound 4). NMR, 
and Mass Spectrum were used to confirm the structure and the purity of 
19
F-FPAMT in 
Figure 4.9 and Figure 4.10. 
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Figure 4.9 Synthesis scheme of 
18/19
F-FPAMT 
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Figure 4.10 NMR analysis of 
19
F-FPAMT 
 
 
Figure 4.11 Mass spectrum of 
19
F-FPAMT 
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4.3.2 Manually synthesis of 
18
F-FPAMT 
[
18
F]Fluoride in kryptofix complex (100 mCi in 0.3 mL acetonitrile) was purchased 
from the cyclotron facility of Cyclotope (Houston, TX, USA). N-t-butoxycarbonyl-O-[3-
tosylpropyl]-α-methyl tyrosine ethyl ester (2.0 mg; 3.83 μmol) dissolved in acetonitrile 
(0.1 mL) was added to the [
18
F]fluoride-kryptofix complex (51.5 mCi). The reaction 
mixture was heated at 90°C for 15 min to allow the displacement to occur. After the 
reaction mixture cooled, it was passed through a 500 mg silica gel packed SPE column 
(Whatman Lab., Clifton, NJ, USA) and eluted with acetonitrile (2.0 mL). The acetonitrile 
was then evaporated in vacuo at 85°C. The resulting mixture was hydrolyzed with 
trifluoroacetate (0.2 mL) in dichloromethane (0.2 mL) at room temperature for 10 min 
to deprotect BOC. After the solvent was evaporated to dryness in vacuo, sodium 
hydroxide (1 N; 0.2 mL) in methanol (0.2 mL) was added and heated at 90°C for 15 min 
to remove ethyl ester group. After methanol evaporated, hydrochloric acid (0.1 N; 
0.2 mL) was used to adjust the pH of the final product to 6.5. Radio-TLC was performed 
to assure the radiochemical purity of 
18
F-FPAMT (Figure 4.11).  
 
Figure 4.12 Radio-TLC analysis
 
of 
18
F-FPAMT by manually synthesis 
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4.3.3 Automated synthesis of 
18
F-FPAMT 
The automated radiosynthesis of 
18
F-FPAMT was achieved by our customized 
automated module and its total synthesis recipe is shown in Figure 4.12. The automated 
radiosynthesis consisted of three steps: nucleophilic substitution, deprotection of BOC, 
and deesterification. Before radiosynthesis was completed, the reaction vial 1 (RV1) was 
preloaded with N-t-butoxycarbonyl-O-[3-tosylpropyl]-α-methyl tyrosine ethyl ester 
(6.2 mg; 11.8 μmol), and three syringes were loaded with different solutions: 
acetonitrile (3.0 mL), trifluoroacetate in dichloromethane (2.5 mL; 1 : 1, v/v), and 1N 
sodium hydroxide in ethyl alcohol (3.0 mL; 1 : 2, v/v). For the nucleophilic substitution, 
[
18
F]fluoride-kryptofix complex (29.36 mCi, 0.2 mL) was manually injected into the RV1 
through the injection hole, and additional acetonitrile (0.35 mL) was manually injected 
into the RV1 to flush the residual [
18
F]fluoride-kryptofix complex inside the flow channel. 
Following this step, the infrared (IR) heater automatically heated the RV1 at 90°C for 
15 min. For free fluoride separation, the mixture in the RV1 was automatically passed 
through a 500 mg silica gel packed SPE column (Whatman Lab., Clifton, NJ, USA) to the 
reaction vial 2 (RV2) via nitrogen flow. Additional acetonitrile (2.0 mL) was then added 
to RV1, and the residual mixture was filtered through a SPE column to remove the free 
fluoride. The solution inside RV2 was evaporated in vacuo at 90°C for 15 min before 
deprotection of BOC was performed. Trifluoroacetate in dichloromethane (0.4 mL; 1:1, 
v/v) was loaded into RV2, and the solution was set under room temperature for 10 min 
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to allow the reaction to finish. The solvent was then evaporated to dryness in vacuo for 
15 min. For deesterification, 1N sodium hydroxide in methanol (0.6 mL; 1:1, v/v) was 
loaded into RV2. The reaction mixture in RV2 was heated at 90°C for 15 min. Once 
deesterification was completed, the solvent in RV2 was evaporated in vacuo, and the 
radioactivities of the solvent in the column, RV1, and RV2 were measured upon the 
completion of 
18
F-FPAMT. Radio-TLC was performed to assure the radiochemical purity 
of 
18
F-FPAMT (Figure 4.13). 
 
 
 
Figure 4.13 Automated synthesis recipe of 
18
F-FPAMT 
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Figure 4.14 Radio-TLC analysis
 
of 
18
F-FPAMT by automated synthesis 
 
4.4 Synthesis of 
18/19
F-FTP 
4.4.1 Synthesis of 
19
F- FTP 
The synthetic scheme of [
18/19
F]fluoropropoxytryptophan (
18/19
F-FTP) is shown in 
Figure 4.14.  Three steps were involved in the synthesis. In step 1, thionyl chloride (SOCl2, 
2.4 ml, 34 mmol) was dissolved in anhydrous methanol (100 ml) and cooled to 0°C. 5-
Hydroxytryptophan (5.00 g, 22.7 mmol) was added in portions. After temperature 
returned to room temperature, the mixture was refluxed overnight. The solvent was 
evaporated, followed by silica-gel packed column chromatographic purification using 
ethyl acetate/hexane (4:1, v/v) as an eluent to yield 5-hydroxytryptophan methyl ester 
hydrochloride 5.18 g (84% yield). 
1
H-NMR (300MHz, CDCl3): 7.23 (d, J=8.7Hz, 1H), 7.15 (s, 
1H), 6.91 (d, J=2.1Hz, 1H), 6.73 (dxd, J=8.7, J'= 2.3Hz, 1H), 4.29 (t, J=6.3, 1H), 3.83 (s, 3H), 
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3.26-3.42 (m, 2H). 13C-NMR (300MHz, CDCl3): 169.8, 150.8, 132.2, 127.9, 125.4, 112.2, 
112.1, 105.6, 102.1, 53.5, 52.7, 26.7.  
 
Figure 4.15 Synthesis scheme of 
18/19
F-FTP 
Subsequently, 5-hydroxytryptophan methyl ester (2.4 g, 10 mmol) was dissolved 
in anhydrous dimethylformamide (DMF, 100 mL). Anhydrous triethyl amine (TEA, 4 ml, 
30 mmol) was added while stirring. Ditertbutyl dicarbonate ((Boc)2O, 2.6 g, 12 mmol) 
was then added to the solution. The mixture was stirred and heated at 60°C overnight. 
The reaction mixture was evaporated under reduced pressure and was reconstituted in 
ethyl acetate. The crude product solution was loaded on a silica gel column and eluted 
with ethyl acetate/hexane (from 1:3 to 2:3, v/v). N-Boc-5-Hydroxytryptophan methyl 
ester was collected after solvent evaporation to yield 3.08 g (92% yield). 1H-NMR 
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(300MHz, CDCl3): 7.05 (d, J=8.7Hz, 1H), 6.90 (s, 1H), 6.84 (d, J=2.1Hz, 1H), 6.56 (dxd, 
J=8.7, J'= 2.3Hz, 1H), 4.30 (t, J=6.3, 1H), 3.56 (s, 3H), 2.90-3.10 (m, 2H), 1.29 (s, 9H).  
In step 2, an aliphatic tosyl chain was to be added at phenolic hydroxyl group of 
N-Boc-5-hydroxytryptophan methyl ester. Cesium carbonate (CsCO3, 3.9 g, 12 mmol) 
was added to N-Boc-5-hydroxytryptophan methyl ester (3.4 g, 10 mmol) in 60 ml of 
anhydrous DMF while stirring under nitrogen atmosphere. 1,3-ditosyl-propanol (6.2 g, 
16 mmol) was added to the solution. The mixture was stirred for overnight at 60°C. The 
reaction mixture was evaporated under reduced pressure and was reconstituted in ethyl 
acetate. The crude product solution was loaded on a silica gel column and eluted with 
ethylacetate /hexane (from 1:3 to 2:3, v/v) to yield 4.6 g (84% yield) of N-Boc-
tosylpropoxytryptophan methyl ester (Tso-TP/Boc/Ester). NMR was used to confirm the 
structure of Tso-TP/Boc/Ester (Figure 4.15). 1H-NMR (300MHz, CDCl3): 7.77 (d, J=8.3Hz, 
2H), 7.24 (d, J=8.8Hz, 1H), 7.19 (d, J=8.3Hz, 2H), 6.97 (s, 1H), 6.91 (d, J=2.4Hz, 1H), 6.70 
(dxd, J=8.8, J'= 2.4Hz, 1H), 4.53 (m, 1H), 4.28 (t, J=6.3Hz, 2H), 4.00 (t, J=5.8Hz, 2H), 3.67 
(s, 3H), 3.21 (d, J=5.2, 2H), 2.34 (s, 3H), 2.13 (quintet, H=6.0Hz, 2H), 1.41 (s, 9H). Mass 
spectrometry (M+): 545.5 (100%), 445.4 (5%), 171.2 (10%), 105.2 (10%). 
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Figure 4.16 NMR Analysis of Tso-TP/Boc/Ester 
In step 3, N-Boc-tosylpropoxytryptophan methyl ester was reacted with 
potassium fluoride in 2,2,2-kryptofix, followed by de-protection. N-Boc-
tosylpropoxytryptophan methyl ester (50 mg, 0.09 mmol), potassium fluoride (10.5 mg, 
0.18 mmol) and 2,2,2-kryptofix (34 mg, 0.09 mmol) were dissolved in anhydrous 
acetonitrile (5 mL) while stirring under nitrogen atmosphere and was refluxed for 4 hrs. 
The reaction mixture was evaporated under reduced pressure and reconstituted in ethyl 
acetate (0.5 ml), and purified with column chromatography using hexane in  ethyl 
acetate (1:1, v/v) to obtain 15 mg (43% yield) of N-Boc-fluoropropoxytryptophan methyl 
ester (FTP/Boc/Ester). NMR and Mass Spectrum was used to confirm the structure of 
FTP/Boc/Ester (Figure 4.16 & Figure 4.17). 1H-NMR (300MHz, CDCl3): 7.16 (d, J=8.8HJz, 
1H), 6.95 (s, 1H), 6.91 (d, J=2.3Hz, 1H), 6.78 (dxd, J=8.8, J'= 2.3Hz, 1H), 5.02 (d, 2H), 4.69 
(t, J=5.9Hz, 1H), 4.53 (t, J=5.9Hz, 1H), 4.07 (d, J=5.1Hz, 2H), 3.61 (s, 3H), 3.21 (d, J=5.1, 
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2H), 2.17 (quintet, H=6.0Hz, 1H), 2.08 (quintet, H=6.0Hz, 1H), 1.35 (s, 9H). Mass 
spectrometry (M+): 393.3 (50%), 248.8 (10%), 172.8 (20%), 140.8 (30%), 112.6 (100%). 
 
Figure 4.17 NMR analysis of 
19
F-FTP/Boc/Ester 
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Figure 4.18 Mass spectrum of 
19
F-FTP/Boc/Ester 
To de-protect amino and ester groups, N-Boc-fluoropropoxytryptophan methyl 
ester (15 mg, 0.038 mmol) was dissolved in the mixture of dichloromethane and 
anhydrous trifluoroacetic acid (0.5ml; 1:1, v/v).  The mixture was stirred for 60 min. 
After solvent evaporation, NaOH (1N 0.5ml) was added to the residue. The reaction 
mixture was heated at 85°C for 60min. The product was purified by prep-TLC (1 mm) 
using MeOH: EtOAC (1:3, v:v) to yield fluoropropoxytryptophan (FTP, 5.5 mg, 44%). NMR 
and HPLC were used to confirm the structure of 
19
F-FTP (Figure 4.18 & Figure 4.19). 
1
H-
NMR (300MHz, CDCl3): 6.97 (s, 1H), 6.91 (d, J=2.4Hz, 1H), 6.70 (dxd, J=8.8, J'= 2.4Hz, 1H), 
4.53 (m, 1H), 4.28 (t, J=6.3Hz, 2H), 4.00 (t, J=5.8Hz, 2H), 3.67 (s, 3H), 3.21 (d, J=5.2, 2H), 
2.13 (quintet, H=6.0Hz, 2H).  
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Figure 4.19 NMR analysis of 
19
F-FTP 
 
Figure 4.20 HPLC analysis of 
19
F-FTP 
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4.4.2 Manually synthesis method of 
18
F- FTP 
[
18
F]Fluoride in kryptofix complex (110 mCi in 0.3 mL acetonitrile) was purchased from 
the cyclotron facility of Cyclotope (Houston, TX, USA). N-Boc-tosylpropoxytryptophan 
methyl ester (3.3 mg; 6.16 μmol) dissolved in acetonitrile (0.1 mL) was added to the 
[
18
F]fluoride-kryptofix complex (97.4 mCi). The reaction mixture was heated at 85°C for 
20 min to allow the displacement to occur. After the reaction mixture cooled, it was 
passed through a 500 mg silica gel packed SPE column (Whatman Lab., Clifton, NJ, USA) 
and eluted with acetonitrile (2 mL). The acetonitrile was then evaporated in vacuo at 
85°C. The resulting mixture was hydrolyzed with trifluoroacetate (0.5 mL) in 
dichloromethane (0.5 mL) at room temperature for 10 min to deprotect BOC. After the 
solvent was evaporated to dryness in vacuo, sodium hydroxide (1 N; 0.25 mL) in 
methanol (0.25 mL) was added and heated at 85°C for 15 min to remove ethyl ester 
group. After methanol evaporated, hydrochloric acid (0.1 N, 0.2 mL) was used to adjust 
the pH of the final product to 6.5. HPLC were performed to assure the purity and 
identity of the product (Figure 4.20). The 
18
F- FTP radioactivity at the end of synthesis is 
17.2 mCi, and the radiochemical yield at end of synthesis is 31.17%.  
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Figure 4.21 Radio-HPLC analysis of 
18
F-FTP by manual synthesis 
4.4.3 Automated synthesis method of 
18
F- FTP 
The synthetic scheme is the same as that of cold FTP (Figure 4.14). [
18
F]Fluoride was 
produced by proton irradiation of enriched [
18
O]-water (Sigma Chemical Company, St. 
Louis, MO) in a small-volume silver target.  Aliquots containing 120 mCi of 
18
F activity 
were combined with 26 mg kryptofix-2,2,2 and 4.6 mg anhydrous potassium carbonate, 
heated under reduced pressure to remove the excess [
18
O]-water, and dried by 
azeotropic distillation with acetonitrile (3 x 1.5 mL). K
18
F/kryptofix complex was 
reconstituted in acetonitrile (0.3 mL). The automated synthesis recipe of 18F-FTP is 
shown in Figure 4.21. N-Boc-tosylpropoxytryptophan methyl ester (5 mg) was preloaded 
in the reaction vial (RV1) of this module, and an aliquot of K
18
F/kryptofix in acetonitrile 
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(16.7 mCi, 0.1 mL) was then administered to the RV1 via the external injection port. The 
IR heater automatically warmed the RV1 at 90°C for 15 min.  The mixture in the RV1 was 
passed through a 500mg silica gel packed SPE column (Whatman Lab, Clifton, NJ) and 
eluted with ethyl acetate (1.0 mL) to the reaction vial 2 (RV2) under nitrogen flow to 
remove free fluoride.  Before de-BOC, the solution inside the RV2 was evaporated under 
vacuum at 90°C for 15 min. After that, trifluoroacetate (0.2 mL) in dichloromethane (0.4 
mL) was loaded into the RV2 to deprotect amino group. The solution was set under 
room temperature for 10 minutes to allow for the reaction to complete and then the 
solvent was evaporated to dryness under vacuum for 15 minutes. For de-esterfication, 
ethyl alcohol (0.4 mL) and 1N NaOH (0.2 mL) were added into RV2.  The hydrolysis of the 
ester group was performed at 90°C for 15min.  The solution in RV2 was evaporated 
under reduced pressure. 
18
F-FTP was reconstituted in water (1.2 mL) and filtered 
through a 0.22 µm-filter. The activities of column, RV1 and RV2 were counted upon 
completion of the synthesis. HPLC were performed to assure the purity and identity of 
the product (Figure 4.22). The 
18
F- FTP radioactivity at the end of synthesis is 3.85 mCi, 
and the radiochemical yield at end of synthesis is 22.37%.  
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Figure 4.22 Automated synthesis recipe of 
18
F-FTP 
 
 
Figure 4.23 Radio-HPLC analysis of 
18
F-FTP by automated synthesis 
 
91 
 
4.5 Discussion 
4.5.1 Discussion of synthesis of 
68
Ga-ECG 
68
Ge/
68
Ga generator can provide 
68
Ga
3+
 in 0.1M HCl, and the free hydrated Ga
3+
 
ion is stable only under acidic conditions. When the pH in this solution changes to 3-7, 
Ga
3+
 forms insoluble gallium hydroxide. That condition was observed during synthesis of 
68
Ga-ECG w. Initially, Ga
3+
 elution was added into the vials containing ECG, and the vial 
was heated to stabilize 
68
Ga-ECG. Then NaHCO3 was added into the vial to adjust the pH 
to 5-6 value after heating. The radiochemical purity of 
68
Ga-ECG in this method only 
reached 30% (Figure 4.23). To solve this problem, NaHCO3 was added into the vial 
before the vial was heated. Finally, this method provided high radiochemical purity of 
68
Ga-ECG, and can be easily practiced on this automated synthesis module.   
 
Figure 4.24 Radio-TLC analysis of 
68
Ga-ECG with gallium hydroxide 
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4.5.2 Discussion of synthesis of 
18
F-FPAMT & 
18
F-FTP 
The traditional method for the synthesis of 
18
F-labeled tyrosine analogs such as 
18
F-FET and 
18
F-FAMT was through the electrophilic substitution reaction which provides 
low yield (84, 85). Besides, the reaction uses 
18
F-F2 gas, and HPLC separation makes it 
even difficult to apply this method in automated modules. Although a nucleophilic 
reaction could result in a high yield of 
18
F-FET, this method still requires HPLC for 
purification (86). Thus, it is not ideal to use this synthesis method in automated 
synthesis modules. In this study, we obtained 
18
F-FPAMT and 
18
F-FTP by  nucleophilic 
reactions without HPLC purification. Therefore, our method for the synthesis of 
18
F-
FPAMT and 
18
F-FTP can be applied to the multi-purposed automated synthesis module.  
Table4.1 shows the result comparisons between the manual synthesis and the 
automated synthesis of 
18
F-FPAMT; Table 4.2 shows the result comparisons between 
the manual synthesis and the automated synthesis of 
18
F-FTP. The pH value and 
radiochemical yield of each radiopharmaceutical by manual and automated syntheses 
were similar. However, the yield, the specific activity, and the synthesis time of these 
two drugs made by the manual synthesis were different from the automated synthesis. 
For the specific activity issue of these two radiopharmaceuticals, the amount of starting 
material of the manual synthesis was less than automated synthesis, but the 
radioactivity of K
18
F/kryptofix in automated synthesis was less than in manual synthesis. 
Therefore, the specific activity of the automated synthesis was lower than manual 
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synthesis. For manual syntheses of radiopharmaceuticals, the shorter synthesis time 
often demonstrates higher yield. But the automated synthesis results of 
18
F-FPAMT and 
18
F-FTP showed low yields no matter how soon the synthesis completed. The reason for 
the low yield is that residues of 
18
F-FPAMT & 
18
F-FTP were trapped inside the SPE 
columns. The columns were designed only to absorb unreacted K
18
F/krytofix mixtures. 
To reduce this problem, an optimization process is designed for adjustment of the 
solution retention time inside the SPE column which is influenced by N2 flow rate. 
Instead of the current steady pressure flow, the stepwise profile of N2 flow rate should 
be the key point to increase the yield by automated synthesis.  
 
 
 
Table 4.1 
18
F-FPAMT Result comparisons between manual synthesis and automated 
synthesis 
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Table 4.2 
18
F-FTP Result comparisons between manual synthesis and automated 
synthesis 
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5 Chapter 5 Discussion 
On March 10, 2000, FDA announced 
18
F-FDG to be a safe and effective PET drug for 
certain indications when it produced in a qualified condition(87). The qualified condition 
is followed by current Good Manufacturing Practice (cGMP) regulations (88), and an 
automated synthesis module with validated specifications is to produce certified 
18
F-
FDG. In addition, 
18
F-FDG produced by an automated synthesis module is housed in a 
hot cell that reduces the radiation exposure of employees. Though, 
18
F-FDG PET is useful 
in disease detection. However, it has the limitations in tumor diagnosis, such as 
differentiations between tumors and inﬂammatory tissue (89-91), and the 
differentiation of low-grade gliomas (92-94). As a result, there are strong clinical 
demands to use other radioactive drugs to overcome these limitations or to be 
employed in other clinical applications (19, 95-100). In order to achieve clinical demands, 
the design of an automated synthesis module can not only serve for a special synthesis 
recipe which is used to produce one special drug, such as 
18
F-FDG (101). Therefore, the 
novel automated multi-purpose synthesis module is proposed and validated by 
production of three different PET radiopharmaceuticals which provides the possibilities 
to make up for the deficiency of 
18
F-FDG.  
5.1 Future work for hardware improvement 
After validation of the automated synthesis module, there are three hardware aspects 
which could be improved in the future, the design for easy maintenance, the design for 
upgrading, and the dead volume issue. 
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5.1.1 The design for easy maintenance  
Our initial hardware design concept of this module is straightforward, and this 
concept is that the components of the hardware can provide the functions to replace 
the manual synthesis of radiopharmaceuticals. However, the current feature of design 
doesn’t include the easy maintenance. The maintenance process is very time-consuming 
because of the fixed outer shell and the compact configuration of inside components. In 
order to solve this problem, the physical appearance of this module can be constituted 
by several removable sheets instead of the fixed outer shell, and the new design of the 
inner configurations of this module should provide engineers more accessibility of the 
hardware components.  
 
5.1.2 The design for upgrading 
The current design of this module is a proof of concept for the automated 
synthesis of three different radiopharmaceuticals. In order to synthesize other 
radiopharmaceuticals with complicated recipes or to improve the synthesis 
performance in the future, it is necessary that the hardware design is cable of upgrading. 
The upgrading of this module should provide the users extra functions or better 
performance of the existing functions.  The one possible extra function is to use the 
webcam for monitoring this module during the synthesis, and the dynamic video can be 
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transformed to serious grey-scale pictures which can be compared to the images of the 
standard processes. Therefore, this function can provide extra safety control. For 
existing functions, different types of IR heaters and mass flow controllers can be 
selected to increase the performance of this module. Other than upgrading the 
functions of this module, it is also important to upgrade the injection panel. For this 
current module, radiochemists can perfect its synthesis result by modifications of the 
parameters, and transfer this final recipe for clinical usages. However, it is better to 
design a dual-use replaceable panel which not only keeps the current syringe-type panel 
for optimization of the synthesis recipe but also can be replaced to a kit-type panel for 
clinical usages. In addition, this dual-use panel can provide radiochemists incentives to 
practice the new synthesis recipes on this module because the process of optimization 
for synthesis can help them produce the synthesis kits for different 
radiopharmaceuticals.   
 
5.1.3 The dead volume issue 
Comparisons of the results of automated synthesis and manual synthesis, it 
demonstrates the radiochemical yield of automated synthesis is lower than manual 
synthesis. The major reason is the dead volume issue, and some solutions were stuck 
inside the automated module. Multiple tests were to determine the effect of dead 
volume issue. First, the radioactivity of 
99m
Tc-pertechnetate (1 mL) was measured, and 
injected into this module through the injection port. Then, this solution was 
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automatically transferred to the final product vial through RV1, and RV2, and flow 
channels.  The average radioactivity of the final product vial was 90% of the initial 
radioactivity. The approximately 100 µl solution can be trapped inside the automated 
module even if N2 gas was used to purge the flow channels. For next generation of this 
automated synthesis module, less passages of flow channels can ameliorate this 
problem to improve the radiochemical yield.   
5.2 Future work for software improvement 
The software improvement includes the increase the stability, the software 
development for hardware upgrade and the new design of the user interface.  
 
5.2.1 Increase the stability 
The stability of this automated synthesis module includes two aspects, the 
stability of the software, and the stability of the interaction between hardware and 
software. In addition, the stability of the hardware of this module depends on assurance 
of its individual component which is described in its specifications.  
For traditional programming language, such as C, the compiling order is from the 
first line to the last line. However, the labview is a graphic-based programming language. 
The compiling order of labview is based on the character of sub-programs, and the 
graphic position. Therefore, the wrong sequence of sub-programs compiling produces 
the “racing” event which causes the software unstable or CPU overdrive.  
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The other reason causes the software unstable is the interaction between 
hardware and software. The compiling time for sub-programs often takes microseconds, 
but scanning frequency of the sensors or movable components takes milliseconds. The 
difference will cause the system unstable. A “time-delay” sub-program can slow down 
the speed of software processing, and reorder the sequence of sub-programs compiling. 
The solution can allow the programs response functionally after receiving all the signals 
from hardware components.  
5.2.2 The software development for hardware upgrade and the new design of the 
user interface. 
In section 5.1, the new injection panel and a webcam are the possible direction 
of the hardware upgrade. This hardware upgrade must be accomplished with the 
software upgrade for increase the performance of the next generation module. The new 
user interface of the next generation module should provide the user the real-time 
imaging of the module. In addition, a diagram of this module will be completed and this 
diagram should be animated for visualization of the synthesis process.  
 
5.3 Conclusion 
Initially, radiochemists synthesize the radiopharmaceuticals for translational and 
preclinical usages occasionally. After FDA approval for the specific radiopharmaceutical 
in clinics, the demand of this radiopharmaceutical is increased. However, this high 
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demand might cause radiochemists with the high risk of radiation overexposure. In 
addition, most PET radiopharmaceuticals are made by organic syntheses which take 
longer synthesis time than traditional SPECT radiopharmaceuticals. An automated 
synthesis module is the solution for high demands of FDA-approved PET 
radiopharmaceuticals. Currently, there are 46 FDA-approved radiopharmaceuticals, and 
only 6 radiopharmaceuticals are used in PET applications. Most commercialized 
automated synthesis modules were designed to synthesize these FDA-approved PET 
radiopharmaceuticals, and it is difficult for researchers to modify these modules to 
synthesize its own radiopharmaceuticals. Here, we designed an automated multi-
purposes synthesis module which can provide the essential synthesis functions to 
researchers who is used to synthesizing radiopharmaceuticals manually, and allow 
researchers to optimize the synthesis recipes by this module. Moreover, this module 
also can provide clinical services by modification its software.  
68
Ga-ECG, 
18
F-FPAMT, and 
18
F-FTP were selected to validate the concept of 
automated multi-purposes synthesis module. Nonradioactive manual synthesis of these 
three compounds were processed, and the structure analyses of 
69
Ga-ECG, 
19
F-FPAMT, 
and 
19
F-FTP were demonstrated. After that, 
68
Ga-ECG, 
18
F-FPAMT, and 
18
F-FTP were 
synthesized manually and automatically. The results showed the radiochemical purity of 
these compounds made from automated syntheses was identical as the manual 
syntheses. However, the yield of automated syntheses were lower than those of manual 
synthesis because of the dead volume issue.  
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